Physician profile
Danielle Polvanov
NPI 1518634948
$3,851.91
in general payments reported to CMS, 2019-2025
17 companies · $556 in 2025
The $556 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.31 · 2022: $588 · 2023: $1,862 · 2024: $774 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934 · Travel and Lodging: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.81 |
| Travel and Lodging | $1,258.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,057.14 | 2022-2025 | Tryptyr, Eysuvis, Precision 1 |
| Bausch & Lomb Americas INC. | $428.16 | 2023-2025 | Miebo, Infuse, Biotrue |
| Sun Pharmaceutical Industries INC. | $251.21 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $224.75 | 2022-2024 | Acuvue |
| Oyster Point Pharma, INC. | $205.03 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyepoint US, INC. | $143.26 | 2022 | |
| Coopervision INC. | $121.92 | 2022-2025 | Misight Contact Lens |
| Biotissue Holdings INC. | $76.31 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.31 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $69.29 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $48.42 | 2024-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $43.44 | 2022 | |
| Abb Con-Cise Optical Group LLC | $34.10 | 2025 | Contact Lens |
| Novartis Pharmaceuticals Corporation | $22.46 | 2023 | |
| Amgen INC. | $21.71 | 2024 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $17.55 | 2025 | Iyuzeh |
| Harrow Eye, LLC | $15.85 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Polvanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.